Fractyl Health Inc(GUTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.12 | Insider Own | 15.01% | Shs Outstand | 13.2M | Perf Week | -22.61% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -37.72% | Insider Trans | 13.45% | Shs Float | 11.3M | Perf Month | -85.74% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -1.5 | Inst Own | 38.96% | Short Float | 2.35% | Perf Quarter | -89.25% |
| Income | -0.11B | P/S | - | EPS this Y | 81.17% | Inst Trans | - | Short Ratio | 0.6 | Perf Half Y | -87.68% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 42.51% | ROA | -146.75% | Short Interest | 0.27M | Perf YTD | -96.63% |
| Book/sh | -0.13 | P/C | 0.25 | EPS past 3/5Y | -11.62% -16.69% | ROE | -778.33% | 52W High | -96.97% ($29.34) | Perf Year | -94.21% |
| Cash/sh | 3.55 | P/FCF | - | Sales past 3/5Y | - | ROIC | -196.04% | 52W Low | 4.58% ($0.85) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 46.66% | Gross Margin | - | Volatility(W/M) | 13.33% 13.83% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.45 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.15 | EPS Q/Q | 71.69% | Profit Margin | - | RSI (14) | 14.77 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.15 | Sales Q/Q | - | SMA20 | -70.19% ($2.99) | Beta | 2.52 | Target Price | $41.2 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/10 | SMA50 | -84.52% ($5.75) | Rel Volume | 1.33 | Prev Close | $0.88 |
| Employees | 100 | LT Debt/Eq | - | EPS/Sales Surpr. | -18.52% - | SMA200 | -89.02% ($8.11) | Avg Volume(3M) | 0.44M | Price | $0.89 |
| IPO | 2024/2/2 | Option/Short | No/Yes | Trades | 1199 | Volume | 582,046 | Change | 1.14% |
🧬 Fractyl Health (GUTS) is a U.S. clinical-stage metabolic therapeutics company targeting metabolic diseases such as obesity and type 2 diabetes. With two main pillars—the Revita endoscopic duodenal resurfacing procedure platform and the Rejuva pancreas-targeted gene therapy platform—it is addressing the unmet needs that remain after glucagon-like peptide (GLP)-based drugs, focusing on weight maintenance and fundamental metabolic improvement.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded more than usual. That is 133% of its average volume.
GUTS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +81.2% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 39.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #494 of 594 in the industry
Based on market cap of $12M.
HIND#492 Vyome Holdings Inc $12M PER - 
TVRD#493 Tvardi Therapeutics Inc $12M PER - GUTS#494 Fractyl Health Inc $12M PER - 
CLRB#495 Cellectar Biosciences Inc $12M PER - 
LTRN#496 Lantern Pharma Inc $12M PER - 
FAQ
What kind of company is GUTS?
GUTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GUTS?
The market cap of GUTS is approximately $12M, ranking 5,389 within its sector.
What is the 52-week high and low for GUTS?
GUTS has recorded a 52-week high of $29.34 and a low of $0.85.
